IRVINE, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the signing of a preferred partner agreement with Hive Medical (Hive). Hive’s software suite leverages AI, machine-learning, SMS, and patient self-service technology to increase patient volume.

“Our agreement with Hive is expected to significantly improve our patient engagement strategy, which we know, through our experience, is key to driving Lap-Band^® surgeries,” stated Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences. “We believe that incorporating the Hive platform will enhance lead nurturing and the overall Lap-Band^® experience for patients, by allowing individuals to quickly and easily navigate new patient intake hurdles and book an appointment with a medical professional 24/7/365. This is evidenced in the data we generated during our first quarter 2023 testing of the Hive technology at select Lap-Band^® accounts, where we also have co-op marketing. In fact, integrating the Hive technology into our co-op marketing campaign increased medical consultations by 107% for the select accounts over the previous quarter. Based on these outstanding results, we are excited to immediately roll-out the Hive platform, on an exclusive basis, to additional accounts to better address patient leads, with the intent of increasing conversions and, ultimately, more Lap-Band^® surgeries.”

About ReShape Lifesciences^®
ReShape Lifesciences^® is America’s premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band^® System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. ReShapeCare^™ is a virtual weight-management program that supports lifestyle changes for all weight loss patients led by board-certified health coaches to help them keep the weight off over time. ReShape Marketplace^™ is an online collection of quality wellness products curated for all consumers to help them achieve their health goals. The investigational Diabetes Bloc-Stim Neuromodulation^™ (DBSN^™) system utilizes a proprietary vagus nerve block and stimulation technology platform for the treatment of Type 2 diabetes and metabolic disorders. The Obalon^® balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. For more information, please visit www.reshapelifesciences.com.

Forward-Looking Safe Harbor Statement
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those discussed due to known and unknown risks, uncertainties, and other factors. These forward-looking statements generally can be identified by the use of words such as "expect," "plan," "anticipate," "could," "may," "intend," "will," "continue," "future," other words of similar meaning and the use of future dates. Forward-looking statements in this press release include the statements that we expect our agreement with Hive to significantly improve our patient engagement strategy and lead nurturing. These and additional risks and uncertainties are described more fully in the company's filings with the Securities and Exchange Commission, including those factors identified as "risk factors" in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise, except as required by law.

CONTACTS
ReShape Lifesciences Investor Contact:
Thomas Stankovich
Chief Financial Officer
949-276-6042
ir@ReShapeLifesci.com

Investor Relations Contact:
Rx Communications Group
Michael Miller
(917)-633-6086
mmiller@rxir.com